Effective-compounds of Jinshui Huanxian formula ameliorates fibroblast activation in pulmonary fibrosis by inhibiting the activation of mTOR signaling.

Abstract

BACKGROUND:

Jinshui Huanxian formula (JHF) ameliorates idiopathic pulmonary fibrosis patients. Active compounds, including icariin, isoliquiritigenin, nobiletin, peimine, and paeoniflorin, deriving from JHF were combined as effective-component compatibility ECC of JHF II (ECC-JHF II), which is an effective therapeutic strategy for pulmonary fibrosis (PF) induced by bleomycin (BLM) in rats.

PURPOSE:

This study aimed to explore the underlying mechanism of ECC-JHF II on pulmonary fibrosis.

METHODS:

A model of PF in rats was established through intratracheal instillation of BLM. Pulmonary function, pathological changes, and collagen deposition were examined. The gene and protein expressions in fibroblast activation were detected by quantitative real-time PCR and western blotting respectively.

RESULTS:

ECC-JHF II significantly improved BLM-induced PF in rats, manifested as decreased collagen deposition, reduced pathological damage and improved pulmonary function. Furthermore, ECC-JHF II inhibited fibroblast activation by reducing the expression of α-smooth muscle actin (α-SMA) and fibronectin. We analyzed the targets of ECC-JHF II and differentially expressed genes (DEGs) of fibroblast activation induced by transforming growth factor-β1 (TGF-β1) and found that ECC-JHF II might regulate fibroblast activation by EGFR, PI3K-Akt or mTOR signaling pathway. In vitro experiments, we also found that ECC-JHF II suppressed the mTOR pathway, such as downregulating the phosphorylation levels of p70S6K in fibroblast activation induced by TGF-β1. After activating mTOR signaling, the inhibition of ECC-JHF II on fibroblast activation was blocked. These results suggested that ECC-JHF II potently ameliorated pulmonary fibrosis in rats and effectively suppressed fibroblast activation by interfering with mTOR signaling.

CONCLUSION:

We combined transcriptomics with the network analysis to predict the mechanism underlying ECC-JHF II suppression of fibroblast activation. In summary, ECC-JHF II improved BLM-induced pulmonary fibrosis, which might be associated with the suppression of fibroblast activation by inhibiting the mTOR signaling.

• Authors: Jiansheng Li, Kangchen Li, Yange Tian, Peng Zhao, Xuefang Liu, Minyan Li, Yunping Bai
• Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology (Phytomedicine) Vol. 109 Pg. 154604 (Jan 2023) ISSN: 1618-095X [Electronic] Germany
• PMID: 36610143 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 The Author(s). Published by Elsevier GmbH.. All rights reserved.

Chemical References

• Transforming Growth Factor beta1
• Phosphatidylinositol 3-Kinases
• Bleomycin
• Collagen
• TOR Serine-Threonine Kinases
• mTOR protein, rat

Topics

• Rats
• Animals
• Transforming Growth Factor beta1 (metabolism)
• Phosphatidylinositol 3-Kinases (metabolism)
• Signal Transduction
• Lung
• Bleomycin
• Idiopathic Pulmonary Fibrosis (chemically induced, drug therapy, metabolism)
• Collagen (metabolism)
• Fibroblasts
• TOR Serine-Threonine Kinases (metabolism)